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Obstetric and pediatric pharmacology
urgently need creative, collaborative, mul-
tidisciplinary research approaches to opti-
mize medication use in these vulnerable
patient populations. Optimal use of med-
ications in these populations, in order to
provide greater understanding and confi-
dence for both patients and caregivers, and
training the next generation of pediatric
and obstetric pharmacologists, are our pri-
mary goals.
BACKGROUND
Medication use in children and pregnant
women is generally empiric, based on
data derived from the (non-pregnant)
adult population. Assumptions from
the adult population are embedded
into dosing, efficacy and safety expec-
tations for these populations. Drugs
are almost always developed for adult
patients given the economics that drive
the pharmaceutical industry. The poten-
tial for consideration of use in children
for the same adult indication occurs
later in the drug development pro-
cess (http://www.gpo.gov/fdsys/pkg/BILLS-
112s3187enr/pdf/BILLS-112s3187enr.pdf).
Consideration of indications that exist
only in neonates or during pregnancy
(e.g., necrotizing enterocolitis, respira-
tory distress syndrome, preterm labor,
pre-eclampsia) have enormous long-
term health consequences (Calkins and
Devaskar, 2011) but yet there is little
in the way of approved medications for
any of these conditions, and a paucity
of research in determining the mech-
anisms and potential drug targets for
these indications. Both settings provide
significant challenge for research and
development based on the vulnerability,
size and complexity of these populations.
Traditional thought has been that chil-
dren and pregnant women are healthy
and do not take medications. This is
not the case. Twelve percent of chil-
dren in the US have asthma, and most
children at one time or another have
otitis media, to name two common pedi-
atric conditions. There are approximately
12,000 new pediatric cancer diagnoses a
year, using complex cancer chemother-
apy regimens with medications developed
decades ago. For pregnant women, six is
the average number of medications taken
during a pregnancy (Lee et al., 2006).
Given the later age of pregnancies, and
increase in prevalence in the US, more
women have chronic health conditions
such as Type 2 diabetes mellitus, hyper-
tension, and depression. There are also
pregnancy-related conditions such as ges-
tational diabetes (or undiagnosed Type 2
diabetes mellitus), pre-eclampsia, and pre-
term labor, which although self-limited
can have life-long consequences for the
mother and child. Prevention and treat-
ment of these conditions therefore would
have long-term benefits for both mother
and child.
INNOVATION
Medical treatment of fetal health condi-
tions is an application of both pediatric
and obstetric pharmacology. Two spe-
cific examples are in the prevention of
respiratory distress syndrome by prena-
tally administered progesterone to the
pregnant woman in preterm labor, and
treatment of fetal supraventricular tachy-
cardia (SVT). The various complexities
involved, including diagnosis of fetal SVT,
choice of drug and dose, the various phar-
macokinetic compartments including the
placenta illustrate some of the challenges
of developmental pharmacology (Tavera
et al., 2010).
New drug development which is
informed by fetal drug targets would
potentially prevent undesired off-target
toxicity, while maximizing benefit. The
other side of fetal effects is fetal tox-
icity including fetal malformations.
Determination of developmental tar-
gets, and on- and off-target effects from
drugs, would be highly desirable, in order
to develop new drugs or repurpose old
ones which would be safe for the obstet-
ric population and the developing fetus.
This would be further improved with
mechanistic-based pre-clinical models,
as the precise mechanisms of drug effects
could be identified (Acosta et al., 2013).
Concerns resulting from unwanted
drug effects have weighted the risk: benefit
ratio for new drug development in a more
conservative manner to the detriment of
these populations. Obstetrics continues to
lag behind. Fisk and Atun (2008) demon-
strate this point in a recent publication.
Looking at new drug development from
1980 to 2007, 17 drugs were under devel-
opment for obstetric indications, 660 for
cardiovascular disease (a high-prevalence
indication), and 34 for amyotrophic lat-
eral sclerosis (ALS), which is an orphan
indication. To put this in the proper con-
text, there are approximately 4 million live
births in the US, and with 6–10% com-
plicated by pre-eclampsia and 12% with
pre-term birth; the incidence of ALS is
2:100,000.
Preclinical models have been benefi-
cial for the understanding of drug actions
in vulnerable populations. Extrapolation
from these primarily descriptive mod-
els into humans has been problematic
and sometimes contradicted by human
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experience. Explanations include the lack
of a precise mechanism of drug action,
whether beneficial or harmful; differ-
ent receptors, transporters, or other drug
targets in pre-clinical models; differences
in placentation and placental perfusion
between species; lack of age correlation
between humans and juvenile animal
models; and lack of precise phenotyping.
We remain hopeful that investigation of
developmental and mechanistic models of
drug effect will provide more accurately
predicted human response and specifi-
cally obstetric and pediatric pharmacology
knowledge.
Development of drug targets for is
difficult but necessary for pediatric and
obstetric new drug development. Given
the dynamic nature of these populations,
signaling pathways, receptors and trans-
porters are in constant development and
maturational flux. Attempts must be made
to determine “druggable” pathways or
targets to treat or prevent disease in chil-
dren and during pregnancy. The National
Institutes of Health (NIH) is involved in
developing such targets under its drug
repurposing activities at the National





Consistency and agreement in pheno-
typing and in clinical trial endpoints
is a necessary but difficult concept.
Difficulties in determining efficacy and
safety of medications across clinical trials
using meta-analyses stem from this very
problem- lack of uniformity in nomen-
clature and data definitions though the
necessity of developing adequate method-
ologies is also critical. Phenotyping is
inherently difficult in children and preg-
nant women given the developmental
nature childhood and pregnancy. Carleton
(Shaw et al., 2013) has done a clever job of
connecting pharmacogenomics with drug
safety by using a statistical approach to
candidate genes coupled with consistent
phenotyping. Likewise, an understanding
of clinically relevant sources of variation
in PK and drug response to optimize dos-
ing: integration of pharmacogenomics
and pharmacometric approaches would
be desirable.
Creativity and innovation are required
to develop informative pharmacology
studies, and to make maximum use
of biological samples and clinical data.
Clinical data gathering, whether through
the use of electronic medical records,
paper records or registries, and biolog-
ical sample gathering, using scavenged
samples, as well as other novel methods,
would be highly valuable to potentially
determine subpopulations of responders
and non-responders and development of
potential novel drug targets. Alternative
clinical trial designs, registry trials and
observational designs to improve the
recruitment and retention of study sub-
jects are highly applicable to children
and pregnant women (Shields and Lyerly,
2013).
Biomarkers are needed for pediatric
and obstetric drug development. There is
a paucity of biomarkers for either popula-
tion. The necessity for extended follow-up
of pediatric and obstetric populations to
ensure safety is a primary reason for the
lack of drug development in these pop-
ulations. Development and validation of
biomarkers and surrogate markers is cru-
cial. Again, there is a need to understand
disease processes and on- and off-target
drug effects in order for biomarkers to be
discovered and validated.
Pharmacoepidemiology in pediatric
and obstetrics is critical for defining
exactly what medications patients are tak-
ing and for what conditions. This has
been problematic: medications and indi-
cations have not been generally linked
in claims databases, so it has been quite
difficult to determine the condition that
the medication is being used to treat.
Pharmacoepidemiology can provide the
requisite data granularity regarding what
populations, and subpopulations includ-
ing age and geographic area, are being
prescribed and for what indication(s)
as well as adverse events and drug-drug
interactions associated with medication
use. Coupling pharmacoepidemiologic
knowledge with relationships that define
pediatric disease progression and drug
behavior in children provide a powerful
venue to evaluate the likelihood of clinical
success of new medicines in these target
populations.
Medical informatics as a discipline
has yielded success in the improvement
of therapeutics selection and use and is
being incorporated into medical practices
throughout the US while having been
standard in many parts of the world.
Informing such approaches requires trans-
lational scientists to understand both dis-
ease and population more intimately than
in the past. While IT hurdles continue
to exist, these would seem to be more
surmountable given the investment from
various sources (e.g., hospital information
technology, electronic health records, ven-
dors, new legislation and incentives, third
party payers). A major utility of new infor-
matics databases is, of course, to improve
patient care. Understanding the relation-
ship of medication use to adverse events
in children and pregnant women, as well
as birth outcomes, would be an obvious
benefit (Etwel et al., 2013). Clinical investi-
gation of current practices, in comparison
to presumed best practices, should be pos-
sible and encouraged.
Data bridges between basic, transla-
tional and clinical sciences are needed
to fill gaps in knowledge regarding mecha-
nistic rationale for appropriate medication
use. A mechanistic understanding of drug
disposition and pharmacologic effects,
including adverse reactions related to
drug therapy, must begin at a basic sci-
ence level. Identification of current drug
targets and development of new ones,
both in the fetus, child, and pregnant
woman, are all critical. Incorporation of
pharmacogenetics/genomics approaches
to develop relationships between drug
administration and drug effect (effi-
cacy/toxicity) represents a new frontier
for the development of more targeted
approaches to increase efficacy and reduce
toxicity.
CONCLUSIONS
The adult clinical development paradigm
involves sequential, discrete preclinical
and clinical investigation that ultimately
drives decision making based on achiev-
ing (or not) development milestones. In
contrast, the pediatric setting for drug
development is typically defined by bridg-
ing criteria which is strongly influenced
by the adult evidence for safety and effi-
cacy. Recent US and EU pediatric legis-
lation has caused a shift in this timeline,
moving drug testing for children earlier
in the drug development process. The
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formation of pediatric-centered research
groups within pharma is some indication
that resources for pediatric drug develop-
ment are more appreciated now than in
the past.
The intent of this Journal is to serve
as the voice for the community and also
these understudied and underserved pop-
ulations. We hope that this new journal
will provide a venue for new method-
ologies for data analysis, and alternate
clinical trial designs for small popula-
tions. By encouraging the submission of
publications proposing the development
of innovative study designs and tools to
evaluate medications in these populations,
we endeavor tomove this field of investiga-
tion further. As pharma is developing new
drugs for specific pharmacogenetic sub-
types, the conduct of clinical trials, includ-
ing use of alternative clinical trial designs,
to accommodate small populations could
not be timelier.
There are large knowledge gaps, which
need to be filled in order to best treat
children and pregnant women. We look
forward to developing a creative, interac-
tive publication resource for members of
the pediatric and obstetric research com-
munities in order to improve their health.
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